Skip to main content

Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy

Clinical Trial Grant
Duke Scholars

Awarded By

Novo Nordisk, Inc.

Start Date

April 14, 2026

End Date

January 31, 2029
 

Awarded By

Novo Nordisk, Inc.

Start Date

April 14, 2026

End Date

January 31, 2029